The interaction between pre-admission β-blocker therapy, the Revised Cardiac Risk Index, and mortality in geriatric hip fracture patients
Open Access
- 9 July 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 92 (1) , 49-56
Abstract
BACKGROUND: An association between β-blocker (BB) therapy and a reduced risk of major cardiac events and mortality in patients undergoing surgery for hip fractures has previously been demonstrated. Furthermore, a relationship between an increased Revised Cardiac Risk Index (RCRI) score and a higher risk of postoperative mortality has also been detected. The purpose of the current study was to investigate the interaction between BB therapy and RCRI in relation to 30-day postoperative mortality in geriatric patients after hip fracture surgery. METHODS: All patients older than 65 years who underwent primary emergency hip fracture surgery in Sweden between January 1, 2008, and December 31, 2017, except for pathological fractures, were included in this retrospective cohort study. Patients were divided into cohorts based on their RCRI score (RCRI 1, 2, 3, and ≥4) and whether they had ongoing BB therapy at the time of admission. A Poisson regression model with robust standard errors of variance was used, while adjusting for confounders, to evaluate the association between BB therapy, RCRI, and 30-day mortality. RESULTS: A total of 126,934 cases met the study inclusion criteria. β-Blocker therapy was associated with a 65% decrease in the risk of 30-day postoperative mortality in the whole study population (adjusted incidence rate ratio [95% confidence interval], 0.35 [0.32–0.38]; p < 0.001). The use of BB also resulted in a significant reduction in 30-day postoperative mortality within all RCRI cohorts. However, the most pronounced effect of BB therapy was seen in patients with an RCRI score greater than 0. CONCLUSION: β-Blocker therapy is associated with a reduction in 30-day postoperative mortality, irrespective of RCRI score. Furthermore, patients with an elevated cardiac risk appear to have a greater benefit of BB therapy. LEVEL OF EVIDENCE: Therapeutic/care management, level IIKeywords
This publication has 31 references indexed in Scilit:
- A systematic review of hip fracture incidence and probability of fracture worldwideOsteoporosis International, 2012
- Mortality and cause of death in hip fracture patients aged 65 or older - a population-based studyBMC Musculoskeletal Disorders, 2011
- The 1-Year Mortality of Patients Treated in a Hip Fracture Program for EldersGeriatric Orthopaedic Surgery & Rehabilitation, 2010
- ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac SurgeryCirculation, 2007
- Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate riskCanadian Medical Association Journal, 2005
- A meta-analysis of perioperative beta blockade: What is the actual risk reduction?Surgery, 2005
- Perioperative Beta-Blocker Therapy and Mortality after Major Noncardiac SurgeryNew England Journal of Medicine, 2005
- Derivation and Prospective Validation of a Simple Index for Prediction of Cardiac Risk of Major Noncardiac SurgeryCirculation, 1999
- Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac SurgeryNew England Journal of Medicine, 1996
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987